RNAi screening of the kinome identifies modulators of cisplatin response in ovarian cancer cells

Shilpi Arora, Kristen M. Bisanz, Lourdes A. Peralta, Gargi D. Basu, Ashish Choudhary, Raoul Tibes, David O. Azorsa

Research output: Contribution to journalArticlepeer-review

50 Scopus citations


Objective: Ovarian cancer retains a poor prognosis among the female gynaecological malignancies. It constitutes about 3% of all malignancies in women and accounts for 5% of all female cancer related deaths. A standard treatment is cytoreductive surgery followed by adjuvant chemotherapy, and re-treatment with platinum based chemotherapy at the time of relapse. In order to improve cisplatin response in ovarian cancer cells, we utilized a high-throughput RNAi screening to identify kinase modulators. Methods: A high-throughput RNAi screen was performed using a siRNA library targeting 572 kinases to identify potentiators of cisplatin response in the ovarian cancer cell line SKOV3. Results: RNAi screening identified at least 55 siRNAs that potentiated the growth inhibitory effects of cisplatin in SKOV3 cells. Inhibition of ATR and CHK1 resulted in the greatest modulation of cisplatin response. Drug dose response of cisplatin in the presence of siRNA validated the effects of these target genes. To show that the siRNA data could be successfully translated into potential therapeutic strategies, CHK1 was further targeted with small molecule inhibitor PD 407824 in combination with cisplatin. Results showed that treatment of SKOV3 and OVCAR3 cells with CHK1 inhibitor PD 407824 led to sensitization of ovarian cancer cells to cisplatin. Conclusions: Our data provides kinase targets that could be exploited to design better therapeutics for ovarian cancer patients. We also demonstrate the effectiveness of high-throughput RNAi screening as a tool for identifying sensitizing targets to known and established chemotherapeutic agents.

Original languageEnglish (US)
Pages (from-to)220-227
Number of pages8
JournalGynecologic oncology
Issue number3
StatePublished - Sep 2010


  • ATR
  • CHK1
  • Cisplatin
  • HT-RNAi
  • Ovarian cancer
  • PRKAB1

ASJC Scopus subject areas

  • Oncology
  • Obstetrics and Gynecology


Dive into the research topics of 'RNAi screening of the kinome identifies modulators of cisplatin response in ovarian cancer cells'. Together they form a unique fingerprint.

Cite this